CTNM vs. SKYE

Last updated Apr 2, 2026

Compare and contrast key facts about Contineum Therapeutics, Inc (CTNM) and Skye Bioscience, Inc (SKYE).

Performance

CTNM vs. SKYE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Contineum Therapeutics, Inc (CTNM) and Skye Bioscience, Inc (SKYE). The values are adjusted to include any dividend payments, if applicable.

CTNM vs. SKYE - Yearly Performance Comparison

	2026 (YTD)	2025	2024
CTNM Contineum Therapeutics, Inc	17.67%	-21.98%	-4.87%
SKYE Skye Bioscience, Inc	-11.31%	-73.51%	-74.46%

Fundamentals

EPS CTNM : -$2.20 SKYE : -$1.29
Total Revenue (TTM) CTNM : $0.00 SKYE : $0.00
Gross Profit (TTM) CTNM : -$160.00K SKYE : $0.00
EBITDA (TTM) CTNM : -$61.19M SKYE : -$50.55M

Returns By Period

In the year-to-date period, CTNM achieves a 17.67% return, which is significantly higher than SKYE's -11.31% return.

CTNM

• 1D: 2.99%
• 1M: -12.32%
• YTD: 17.67%
• 6M: 22.16%
• 1Y: 108.20%
• 3Y*: —
• 5Y*: —
• 10Y*: —

SKYE

• 1D: 8.18%
• 1M: -12.64%
• YTD: -11.31%
• 6M: -84.39%
• 1Y: -52.51%
• 3Y*: -46.53%
• 5Y*: -52.99%
• 10Y*: -42.12%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CTNM vs. SKYE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CTNM

CTNM Risk / Return Rank: 75
CTNM Sharpe Ratio Rank: 76
CTNM Sortino Ratio Rank: 79
CTNM Omega Ratio Rank: 73
CTNM Calmar Ratio Rank: 74
CTNM Martin Ratio Rank: 71

SKYE

SKYE Risk / Return Rank: 25
SKYE Sharpe Ratio Rank: 22
SKYE Sortino Ratio Rank: 32
SKYE Omega Ratio Rank: 32
SKYE Calmar Ratio Rank: 17
SKYE Martin Ratio Rank: 21

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CTNM vs. SKYE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Contineum Therapeutics, Inc (CTNM) and Skye Bioscience, Inc (SKYE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CTNM	SKYE	Difference
Sharpe ratio Return per unit of total volatility	1.11	-0.42	+1.53
Sortino ratio Return per unit of downside risk	2.13	0.16	+1.96
Omega ratio Gain probability vs. loss probability	1.25	1.02	+0.23
Calmar ratio Return relative to maximum drawdown	1.86	-0.66	+2.52
Martin ratio Return relative to average drawdown	4.03	-1.05	+5.07
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CTNM vs. SKYE - Sharpe Ratio Comparison

The current CTNM Sharpe Ratio is 1.11, which is higher than the SKYE Sharpe Ratio of -0.42. The chart below compares the historical Sharpe Ratios of CTNM and SKYE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CTNM	SKYE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.11	-0.42	+1.53
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.40	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.31	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.08	-0.36	+0.29

Correlation

The correlation between CTNM and SKYE is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CTNM vs. SKYE - Dividend Comparison

Neither CTNM nor SKYE has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CTNM vs. SKYE - Drawdown Comparison

The maximum CTNM drawdown since its inception was -84.37%, smaller than the maximum SKYE drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for CTNM and SKYE.

Drawdown Indicators

	CTNM	SKYE	Difference
Max Drawdown Largest peak-to-trough decline	-84.37%	-99.96%	+15.59%
Max Drawdown (1Y) Largest decline over 1 year	-49.85%	-87.85%	+38.00%
Max Drawdown (5Y) Largest decline over 5 years	—	-99.07%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-99.83%	—
Current Drawdown Current decline from peak	-38.16%	-99.95%	+61.79%
Average Drawdown Average peak-to-trough decline	-41.32%	-94.87%	+53.55%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.02%	55.54%	-32.52%

Volatility

CTNM vs. SKYE - Volatility Comparison

Contineum Therapeutics, Inc (CTNM) and Skye Bioscience, Inc (SKYE) have volatilities of 23.64% and 23.12%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CTNM	SKYE	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.64%	23.12%	+0.52%
Volatility (6M) Calculated over the trailing 6-month period	50.21%	110.81%	-60.60%
Volatility (1Y) Calculated over the trailing 1-year period	98.03%	125.77%	-27.74%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	85.48%	133.29%	-47.81%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	85.48%	137.34%	-51.86%

Financials